Skip to main content
. 2016 May 10;20(3):126–132. doi: 10.1080/13651501.2016.1179765

Table 1.

Reasons for premature study termination for patients with moderate depression treated with WS® 5570 3 × 300 mg/d or paroxetine.

Reasons for premature discontinuation WS® 5570 (n = 31) Paroxetine (n = 33)
Withdrawal of consent without giving the reason   3 (9.1)
Lack of efficacy   1 (3.0)
Adverse event(s) 1 (3.2) 2 (6.1)
Lost to follow-up   1 (3.0)
Total 1 (3.2) 7 (21.2)

All values are expressed as n (%).